Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade

Los Angeles, USA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade

Glioblastoma Multiforme Clinical Trial Analysis and Pipeline Assessment report offers an analysis of 120+ companies working for the development of therapies for Glioblastoma Multiforme

DelveInsight’s Glioblastoma Multiforme (GBM) Pipeline Insight, 2020 report proffers a comprehensive coverage of all the companies under pipeline and growth prospects across Glioblastoma Multiforme pipeline, collaborations and agreements taking place, in-depth commercial assessment, and competitive analysis. 

Some of the key highlights of Glioblastoma Multiforme Pipeline Report

• The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc.
• The potential candidates with promising results in late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), and Regorafenib (Bayer).
• Ofranergene obadenovec is budding gene therapy with status Orphan Drug Designation from both the US FDA and EMA for the treatment of patients with GBM. The drug has completed phase III stage of clinical development for the patients with recurrent GBM (rGBM).
• Four vaccines/ immunotherapy candidates including VBI-1901 (VBI Vaccines), AV-GBM-1 (Aivita Biomedical) and ITI-1000 (Immunomic Therapeutics), and Tasadenoturev (DNAtrix) are also demonstrating promising results in clinical trials. 

Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which are yet to be launched. 120+ companies are dedicatedly working in advancing the GBM pipeline in the foreseeable future. 

Some of the Glioblastoma Multiforme Pipeline Therapies 

Regorafenib: Bayer Healthcare

Regorafenib is an orally-administered inhibitor of multiple kinases. Sold under the brand name, Stivarga, Regorafenib is approved for use in patients with hepatocellular carcinoma. The drug is currently under investigation for the treatment of Glioblastoma Multiforme which is mentioned. The molecule is in the phase III stage of clinical development.

CYNK 001: Celularity

CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers and solid tumors. The U.S. Food and Drug Administration (FDA) recently cleared Celularity’s Investigational New Drug (IND) Application for CYNK-001 in patients with glioblastoma multiforme (GBM).

Know more about GBM pipeline therapies and product profiles, request @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight

Upcoming Glioblastoma Multiforme Therapies 

• Regorafenib: Bayer
• Trans Sodium Crocetinate (TSC): Diffusion Pharmaceuticals
• Ofranergene obadenovec: VBL Therapeutics
• Tasadenoturev: DNAtrix
• DelMar Pharmaceuticals
• ONC201: Oncoceutics
• Selinexor: KaryoPharma
• Paxalisib: Kazia Therapeutics
• AV-GBM-1: Aivita Biomedical
• MDNA55: Medicenna Therapeutics
• CYNK-001: Celularity 
• Crenolanib: AROG Pharmaceuticals
• Afatinib: Boehringer Ingelheim

Scope of Glioblastoma Multiforme Pipeline Therapeutics report  

• Coverage: Global 
• Major Players: 120+ Key Companies
• Corporate Players: Bayer AG, BeiGene Ltd, Boehringer Ingelheim International GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Co, Cynata Therapeutics Ltd, Cytodyn Inc, CytoVac AS, Denovo, Biopharma LLC, DevaCell Inc, Diakonos Research Ltd, Diffusion Pharmaceuticals Inc, Diverse Biotech Inc, Eli Lilly and Co., Empirica Therapeutics Inc, ENB Therapeutics LLC, EnduRx Pharmaceuticals Inc, EnGeneIC Ltd, F. Hoffmann-La Roche Ltd, Falcon Therapeutics Inc, Faron Pharmaceuticals Oy, Geneius Biotechnology Inc, Genenta Science srl, Genentech Inc, GlaxoSmithKline Plc, i2 Pharmaceuticals Inc, Ibex Biosciences LLC, Immatics Biotechnologies GmbH, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, Immunitor Inc, Johnson & Johnson, Joseah Biopharma Co Ltd, Jubilant Therapeutics Inc, Juno Therapeutics Inc, Merck KGaA, Meryx Inc, Metis Precision Medicine, OncoSynergy Inc, Oncotelic Inc, Oncternal Therapeutics, Ono Pharmaceutical Co Ltd, Pfizer Inc, Phanes Therapeutics Inc, Pharma Mar SA, PharmAbcine Inc, Regeneron Pharmaceuticals Inc, Reglagene LLC, Regulus Therapeutics Inc, ReNeuron Group Plc, Revolution Medicines Inc, Suzhou Stainwei Biotech Inc, Synactix Pharmaceuticals Inc, Synchronicity Pharma Inc, Synermore Biologics Co Ltd, SyntheX Inc, TheraBiologics Inc, Theralase Technologies Inc, Therapeia GmbH & Co KG, Vanquish Oncology Inc, Vascular Biogenics Ltd, Vault Pharma Inc, WindMIL Therapeutics Inc, WPD Pharmaceuticals Inc, X4 Pharmaceuticals Inc, Zata Pharmaceuticals Inc, Amgen, AbbVie and many others.
• Key Drugs: 120+ Pipeline Products
• Phases:  
  • Glioblastoma Multiforme Therapies Late-stage (Phase III)  
  • Glioblastoma Multiforme Therapies (Phase II)
  • Glioblastoma Multiforme Therapies (Phase I) 
  • Glioblastoma Multiforme Therapies Pre-clinical and Discovery stage candidates 
  • Discontinued & Inactive candidates
    
    

• Route of Administration:
  • Inhalation
  • Intravenous
  • Oral
  • Subcutaneous
    
    

•  Molecule types:  
  • Small molecule
  • Proteins
  • Immunotherapies
  • Monoclonal antibodies
    
    

• Product Types:
  • Mono
  • Combination 

Key Questions regarding Current Glioblastoma Multiforme Treatment Landscape and Emerging Therapies Answered in the report  

• What are the current options for Glioblastoma multiforme (GBM) treatment?
• How many companies are developing therapies for the treatment of Glioblastoma multiforme (GBM)? 
• How many Glioblastoma multiforme (GBM) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Glioblastoma multiforme (GBM)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Glioblastoma multiforme (GBM) market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Glioblastoma multiforme (GBM)?  
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Glioblastoma multiforme (GBM) therapies? 
• What are the key designations that have been granted for the emerging therapies for Glioblastoma multiforme (GBM)? 
• How many patents are granted and pending for the emerging therapies for the treatment of Glioblastoma multiforme (GBM)? 

Table of Contents 

Browse Detailed TOC, Emerging Drugs and Key Companies @ Glioblastoma Multiforme Drug Pipeline Landscape

Related Reports 

Recurrent Glioblastoma Market

DelveInsight's "Recurrent Glioblastoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Recurrent Glioblastoma, historical and forecasted epidemiology as well as the Recurrent Glioblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Glioblastoma Market

DelveInsight's 'Glioblastoma - Market Insights, Epidemiology and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Glioblastoma in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

Adrenocortical Carcinoma Market

DelveInsight's "Adrenocortical Carcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adrenocortical Carcinoma, historical and forecasted epidemiology as well as the Adrenocortical Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Malignant Glioma Pipeline

“Malignant Glioma Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Malignant Glioma market. A detailed picture of the Malignant Glioma pipeline landscape is provided, which includes the disease overview and Malignant Glioma treatment guidelines. 

Malignant Glioma Market 

DelveInsight's "Malignant Glioma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Malignant Glioma, historical and forecasted epidemiology as well as the Malignant Glioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pediatric brain tumors Market

DelveInsight's "Pediatric brain tumors - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pediatric brain tumors, historical and forecasted epidemiology as well as the Pediatric brain tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Osteosarcoma Market

DelveInsight’s ‘Osteosarcoma-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.